Showing posts with label Healthcare Markets. Show all posts
Showing posts with label Healthcare Markets. Show all posts



Report Description
According to a 2009 study by the World Health Organization, the U.S. healthcare system ranks 37th among the healthcare systems of 200 countries. The U.S. healthcare expenditure is considered to be one of the highest in the world, accounting for 17.5% of its GDP in 2009, as compared to an average of 8% to 9% in countries of the Organization for Economic Co-operation and Development (OECD).

This has been a major factor necessitating healthcare reform, along with increasing healthcare costs and health premium rates, as well as the high number of the uninsured (about 47 million or approximately 16% of the total population).
President Obama signed the health reform into law in March 2010 to improve the quality and efficiency of healthcare, address the inefficiencies of the existing healthcare structure, and to decrease the number of uninsured people in the U.S. The health reform bill outlines several provisions such as universal health coverage, cost containment, increase in insurance market competition, excise tax on medical device manufacturers, and lower drug costs for Medicaid and Medicare. The health reform provisions thus directly impact the U.S. healthcare industry and its stakeholders.
The report forecasts and analyzes the future impact of the health reforms on the U.S. healthcare industry. This covers direct as well as indirect impacts of the provisions on pharmaceutical, medical devices, and health insurance industries. Indirect impact refers to provisions that do not specifically apply to these industries. Each section offers a strategic analysis of the impact of Obama’s health reforms on the U.S. healthcare structure.

What makes our reports unique?
We provide the longest market segmentation chain in this industry- not many reports provide market breakdown upto level 5.
We provide 10% customization. Normally it is seen that clients do not find specific market intelligence that they are looking for. Our customization will ensure that you necessarily get the market intelligence you are looking for and we get a loyal customer.
We conduct detailed market positioning, product positioning and competitive positioning. Entry strategies, gaps and opportunities are identified for all the stakeholders.
Comprehensive market analysis for the following sectors:
Pharmaceuticals, Medical Devices, Biotechnology, Semiconductor and Electronics, Energy and Power Supplies, Food and Beverages, Chemicals, Advanced Materials, Industrial Automation, and Telecom and IT. We also analyze retailers and super-retailers, technology providers, and research and development (R&D) companies.

Key questions answered
What is the structure of U.S. healthcare system and what are the pitfalls within the current system?
What are the major provisions of the U.S. Healthcare reform?
How would the provisions of healthcare reforms affect U.S. healthcare industry in near future?
What will be the drivers and restraints for different stakeholders of the U.S. healthcare industry in the near future?
What can be the possible business implications for the U.S healthcare industry and its stakeholders such as Pharmaceuticals, Medical device manufacturers and health insurance industry?
What will be the impact of Healthcare reforms on the U.S. economy?

Powerful Research and analysis
The analysts working with MarketsandMarkets come from renowned publishers and market research firms, globally, adding their expertise and domain understanding. We get the facts from over 22,000 news and information sources, a huge database of key industry participants and draw on our relationships with more than 900 market research companies across the world. We, at MarketsandMarkets, are inspired to help our clients grow by providing qualitative business insights with our huge market intelligence repository.

About Us
ReportsandReports comprises an online library of 10,000 reports, in-depth market research studies of over 5000 micro markets, and 25 industry specific websites. Our client list boasts almost all well-known publishers of such reports across the globe. We as a third-party reseller of market research reports employ a number of marketing tools, such as press releases, email-marketing and effective search-engine optimization techniques to drive revenues for our clients. We also provide 24/7 online and offline support service to our customers.

Contact:
Ms. Sunita
7557 Rambler road,
Suite 727, Dallas, TX 75231
Tel: +1-888-989-8004

Original Source: Healthcare Market
Buy Now: Research

Read More

Dallas, TX: ReportsandReports announce it will carry Kazakhstan Pharmaceuticals and Healthcare Report Q3 2010 Market Research Report in its Store.

Browse complete Kazakhstan Pharmaceuticals and Healthcare Report Q3 2010 Report

BMI retains its robust five-year growth forecast for the Kazakhstan pharmaceutical market, with the US dollar value of the market rebounding on the back of a resurgent local currency in 2010. Our forecast sees a strong economy - driven by increasing oil and gas output and anticipated strong global prices for these exports - and appreciating currency over five-year and ten-year forecast periods. BMI calculates a compound annual growth rate (CAGR) in US dollar terms of 17.47% for 2009-2014. Full-year data for 2009 showed an 18-22% boost in market value in local terms, with a slight contraction in US dollar value.

For Kazakhstan’s bureaucrats and pharmaceutical producers, the goal is to deliver tangible increases in domestic production to meet President Nursultan Nazarbayev’s target of ensuring that 50% of medicines, in volume terms, are domestically sourced by 2014. Local production, according to the Farmmedindustriya industry association, increased by 23.4% to KZT12.4bn (US$83.7mn) in 2009. A decisive factor in supporting local output will be state purchasing. State-owned distributor SK Farmatsiya reported an increase in its share of domestically-sourced purchasing in 2009 from 8% to 23%, in volume terms. Officials say the country is on course to meet the 2014 deadline, while the country has adopted an industrial plan for the industry and a number of new production facilities are in the pipeline.

To date there has been little tangible impact from the Customs Union of Kazakhstan, Russia and Belarus launched at the beginning of 2010. BMI’s view is that the union is less important in terms of internal pharmaceutical trade - at least during the forecast period - but a significant player amid plans to harmonise market authorisation and other regulatory standards. Harmonisation, if achieved, could make these three key CIS markets easier to navigate for all players - an important development. However, some major regulatory gaps remain in Kazakhstan, such as the absence of a finalised set of local Good Manufacturing Practice (GMP) standards - despite a 2014 GMP compliance deadline - and a need to develop the country’s formulary system and link it to the Essential Drugs List.

The country’s pipeline of domestic production projects represents, potentially, the most far-reaching development for the local sector since privatisation in the 1990s and BMI estimates the value of current projects at around US$200mn, a multiple of current industry value. Crucially, many of these projects require funding from the Kazakhstan Development Bank (KDB) and National Innovation Fund, as the once-strong private banking sector has yet to recover from the global financial crisis. The furthest advanced project among locals is one by domestic champion Chimpharm to build a new tablet factory in a new industrial park in Astana. The company also has plans to expand production facilities in Shymkent. Other players, including GlobalPharm, Nobel AFF, and Romat are reportedly planning new lines or new plants. If funding can be found in the state and private sector for these projects and the country can remain politically and economically stable, Kazakhstan will have an industry capable of meeting a significant share of local needs and meeting demand in growing regional markets like Uzbekistan.

Executive Summary

SWOT Analysis

Kazakhstan Pharmaceuticals And Healthcare SWOT

Kazakhstan Political SWOT

Kazakhstan Economic SWOT

Kazakhstan - Business Environment Rating

Table: Central And Eastern Europe (CEE) Pharmaceutical And Healthcare Business Environment Ratings, Q310

Limits of Potential Returns

Risks to Realisation of Returns

Kazakhstan - Market Summary

Regulatory Regime

Intellectual Property Environment

Counterfeit Drugs

Pricing and Reimbursement Regime

Table: Price Components And Add-Ons For Imported And Locally Produced Generic Medicines (KZT)

Recent Pricing and Reimbursement Developments

Industry Developments

Epidemiology

Healthcare Sector

Table: Top 10 Manufacturers By Value Of Hospital Purchases

Table: Top 10 INNs By Value Of Hospital Purchases

Healthcare Sector Financing

Table: Top 10 ATC Groups By Value Of Hospital Purchases

Table: Top 10 ATC Groups By Retail Pharmacy Sales

Domestic Pharmaceutical Industry

Recent Domestic Industry Developments

Wholesale and Retail

Recent Wholesale and Retail Developments

Foreign Pharmaceutical Industry

Recent Foreign Industry Developments

Clinical Trials

Medical Devices

Table: Medical Devices Market In Kazakhstan, 2006-2008 (US$mn)

Industry Forecast Scenario

Overall Market Forecast

Key Growth Factors - Industry

Key Growth Factors - Macroeconomic

Table: Kazakhstan - Economic Activity

Prescription Market Forecast

OTC Market Forecast

Patented Market Forecast

Generics Market Forecast

Export/Import Market Forecasts

Other Healthcare Data Forecasts

Key Risks to BMI’s Forecast Scenario

Competitive Landscape

Table: Top 10 Manufacturers By Retail Pharmacy Sales

Table: Top 10 Trade Names By Value Of Retail Pharmacy Sales

Company Monitor

Indigenous Companies

Chimpharm

Romat FK

Foreign Companies

Novartis (Lek & Sandoz)

Sanofi-Aventis

GlaxoSmithKline (GSK)

Nycomed

Merck & Co

Pfizer

Ranbaxy

Country Snapshot: Kazakhstan Demographic Data

Section 1: Population

Table: Demographic Indicators, 2005-2030

Table: Rural/Urban Breakdown, 2005-2030

Section 2: Education and Healthcare

Table: Education, 2002-2005

Table: Vital Statistics, 2005-2030

Section 3: Labour Market and Spending Power

Table: Employment Indicators, 1999-2004

Table: Consumer Expenditure, 2000-2012 (US$)

Table: Average Annual Wages, 2000-2012

BMI Methodology

How We Generate Our Pharmaceutical Industry Forecasts

Pharmaceutical Business Environment Ratings Methodology

Ratings Overview

Table: Pharmaceutical Business Environment Indicators

Weighting

Table: Weighting Of Components

Sources

Forecast Tables

Browse complete Kazakhstan Pharmaceuticals and Healthcare Report Q3 2010 Report

Browse all Pharmaceuticals Market Research Reports

Browse all Business Monitor International Market Research Reports

Browse all Latest Report

Related Reports:

Bangladesh Pharmaceuticals and Healthcare Report Q3 2010

Chile Pharmaceuticals and Healthcare Report Q3 2010

Morocco Pharmaceuticals and Healthcare Report Q3 2010

About Us:
Reports and Reports comprises an online library of 10,000 reports, in-depth market research studies of over 5000 micro markets, and 25 industry specific websites. Our client list boasts almost all well-known publishers of such reports across the globe. We as a third-party reseller of market research reports employ a number of marketing tools, such as press releases, email-marketing and effective search-engine optimization techniques to drive revenues for our clients. We also provide 24/7 online and offline support service to our customers.

Contact:
Ms. Sunita
7557 Rambler road,
Suite 727, Dallas, TX 75231
Tel: +1-888-989-8004
Website: http://www.reportsandreports.com/
Blog: http://reportsnreports.wordpress.com/
Blog: http://reportsandreports.blogspot.com/

Read More